Ibogaine for Ketamine Addiction: What the Evidence Shows
What is known, and what is not yet known, about ibogaine as a possible treatment for ketamine use disorder.
What ketamine use disorder is and who it affects
Ketamine is a dissociative anaesthetic that blocks the brain's NMDA glutamate receptor. It has real medical uses in anaesthesia and pain control, and a related form, esketamine, is licensed for treatment-resistant depression. In the United States, ketamine is a Schedule III controlled substance.
Ketamine use disorder describes a pattern of repeated, often daily, high-dose use. The UK Advisory Council on the Misuse of Drugs (ACMD) describes it as driven by tolerance and dose escalation, together with dependence and withdrawal symptoms on stopping. Most people who use ketamine do so occasionally. Responses to the ACMD's 2025 call for evidence estimated that 5–8% develop problematic, high-dose daily use.
Key figures from the ACMD's January 2026 review:
- Past-year use among 16–59-year-olds in England and Wales rose from 0.5% (2014–15) to 0.9% (2022–23), then fell slightly to 0.8% (about 264,000 people) in 2024–25.
- Over the same decade, the number of people seeking treatment for ketamine use disorder rose 12-fold.
- The peak age group is 20–24. The ACMD also notes use among school-aged children and university students.
- Some people start using ketamine to self-treat pain, anxiety or depression. Ketamine can also cause those problems, which can set up a cycle of escalating use.
Physical harm can also keep people using. Painful bladder damage is a common complication, and the ACMD notes that it can drive further ketamine use for its painkilling effect.
Physical harms: ketamine bladder damage and recovery
Ketamine and its metabolite norketamine pass through the urine and damage the lining of the urinary tract. This condition is called ketamine-induced uropathy (often called "K-bladder"). Symptoms include:
- frequent urination by day and night, and urgency
- incontinence
- burning pain when urinating, and blood in the urine
- bladder pain
About a quarter of people who use ketamine regularly report at least one urinary symptom. UK urologists report rising referrals of adolescents and adults.
Stopping ketamine is the most important part of treatment. Medicines, treatments delivered directly into the bladder, and surgery can also help. The British Association of Urological Surgeons has published consensus guidance and calls for multidisciplinary care that treats the ketamine use disorder alongside the bladder disease.
Recovery is possible but not guaranteed. According to the ACMD, long-term harms may not resolve, or may only partly resolve, after ketamine use stops, and people often do not realise the risk until the damage is done.
Other long-term harms include:
- "K-cramps": abdominal pain, sometimes with vomiting, affecting more than a quarter of regular users.
- Liver and bile-duct injury: occurs in about 10% of regular users. Deaths from conditions such as sclerosing cholangitis and cirrhosis have occasionally been reported.
- Cognitive harm: appears to depend on dose.
Current ketamine addiction treatment options and their outcomes
No medication is approved specifically for ketamine use disorder. The research base for conventional treatment is limited, but that reflects how little research has been done, not evidence that these treatments fail.
A 2026 systematic review by Mosca and colleagues included 73 studies: 5 controlled studies, 15 observational studies, 15 case series and 38 case reports. Its findings:
- Psychosocial treatment: motivational interviewing, cognitive behavioural therapy (CBT) and occupational therapy were used, with varying effectiveness.
- Medications: benzodiazepines, SSRIs, naltrexone, lamotrigine and gabapentinoids were used, mostly off-label.
- Integrated care: models that combine addiction, psychiatric, urological and gastrointestinal care looked the most promising.
- Relapse: rates were high and follow-up was short, which weakens conclusions.
A 2024 systematic review in the Journal of Addiction Medicine focused only on medications. It found 12 studies with 368 participants and rated all of the evidence very low quality.
- Withdrawal: benzodiazepine regimens are the most studied option and the review judged them the most promising area for future trials.
- Craving and relapse prevention: naltrexone, lamotrigine and paliperidone with bupropion have each been described only in case reports.
The ACMD notes that withdrawal after heavy use can last several days. It also says the evidence on managing withdrawal and dependence is limited and low quality.
In practice, the usual route is through a doctor or a specialist addiction service. These can offer a medically supervised withdrawal plan, talking therapies, treatment for depression or anxiety, and a referral to urology when bladder symptoms are present.
Why researchers are studying ibogaine for ketamine addiction
Ibogaine is an alkaloid from the West African shrub Tabernanthe iboga. Interest in it for addiction comes mainly from opioid research and anecdotal reports, not from any research on ketamine.
A 2023 mechanistic review by Ona and colleagues, drawing mostly on laboratory and animal studies, concluded that ibogaine and its long-lasting metabolite noribogaine act on several targets at once. The authors argue that ibogaine is better understood as acting on several receptor systems together than through one key target. Reported targets include:
- NMDA receptors: ibogaine blocks them in laboratory and animal studies. Noribogaine binds less strongly.
- Kappa opioid receptors: both compounds act on them.
- Serotonin transporter and nicotinic α3β4 receptors.
The authors of the only ketamine-specific case report suggest these targets, plus growth-factor signalling linked to brain plasticity (BDNF and GDNF), as possible explanations. They present these explicitly as hypotheses.
There is an unresolved puzzle. Ketamine itself is an NMDA blocker, and no one has explained why a second NMDA-active drug would reduce ketamine craving rather than reinforce its effects. Our searches did not find any animal study testing ibogaine on ketamine self-administration.
Evidence level: mechanistic reasoning, plus one human case report. There are no controlled trials, case series or animal models specific to ketamine.
Published research on ibogaine for ketamine addiction
We found one peer-reviewed publication. Pérez Rosal, Faber and Backmund published a case report in Frontiers in Psychiatry in July 2026.
The case:
- Patient and history: a 30-year-old man with five years of polysubstance use. He used 2–3 g of intranasal ketamine daily, along with cocaine, binge drinking and nicotine. He also had recurrent depression.
- Route to treatment: he left a German psychiatric clinic against medical advice and entered a 13-day residential ibogaine program in Mexico.
- Before dosing: a medical intake, ECGs and a 7-day supervised detox.
- Dosing: an 800 mg ibogaine HCl dose (about 10 mg/kg), followed by two 300 mg booster doses.
- Monitoring: continuous 12-lead ECG, with intravenous magnesium and potassium.
Reported outcomes over about 17 months:
- Self-reported craving fell to zero and stayed there. Repeated urine toxicology was negative for the drugs he had been using.
- Depression, anxiety, PTSD and quality-of-life scores improved.
- Adverse events: QTc rose from 395 ms to a peak of 541 ms despite monitoring and electrolyte prophylaxis, then fell below 500 ms without arrhythmia. He also had transient ataxia, high blood pressure and vomiting.
- At 11 months, after a bereavement, he returned for a second ibogaine treatment.
Limitations stated by the authors:
- It is a single case, so the result cannot be generalised.
- There was no control condition.
- He received integration therapy and nutritional support at the same time.
- The second treatment confounds the long-term results.
- The findings depend partly on self-report.
- Treatment took place in an unregulated setting.
The authors call for controlled trials in regulated settings.
A single good outcome is a reason to do more research. It does not tell us how often ibogaine helps people with ketamine use disorder, or how often it harms them.
What medically supervised ibogaine administration involves
Ibogaine is a Schedule I controlled substance in the United States, so people who seek it usually travel abroad, often to Mexico. Protocols differ between providers, and no regulator has standardised them. Published safety reviews and the case report above describe these elements:
- Screening: a medical history, a baseline ECG to check the QT interval, blood electrolytes (potassium and magnesium) and liver tests, and a full review of all medications and substances.
- Stabilisation before dosing: in the ketamine case report, this meant a week of supervised detox before ibogaine was given.
- Continuous cardiac monitoring: Koenig and Hilber recommend continuous ECG monitoring that lasts well beyond the dosing day, because cardiac events have occurred up to several days afterwards.
- Electrolyte management: this includes intravenous magnesium and potassium.
- Physical support: in a Dutch hospital study, every participant had severe, temporary ataxia and could not walk without support.
- Aftercare: this includes psychological follow-up, continued addiction care and urology follow-up. The case report's authors raise concerns about continuity of care when treatment happens across borders.
This page is educational information, not medical advice, and it does not replace care from a qualified clinician.
Safety: cardiac risks, screening and contraindications
QT prolongation. Ibogaine blocks hERG potassium channels in the heart, which delays the heart's electrical recovery between beats. In the Dutch hospital study of 14 patients (Knuijver et al.), each given 10 mg/kg:
- the average maximum QTc prolongation was 95 ms
- half the patients exceeded 500 ms
- six patients still had prolongation more than 24 hours later
No torsades de pointes occurred in that study. Koenig and Hilber report that, outside it, QTc prolongation has progressed to ventricular tachycardia, ventricular fibrillation and torsades de pointes, sometimes 12–76 hours after dosing.
Deaths. People have died during or after ibogaine treatment, in clinics with medical staff present as well as outside them. Monitoring can catch a dangerous heart rhythm early enough to treat it, but it does not prevent one and can miss one. A forensic review identified 19 deaths between 1990 and 2008, occurring 1.5–76 hours after ibogaine. Most cases with adequate data involved existing heart disease or other substances.
General cardiac risk factors (Koenig and Hilber):
- low potassium or magnesium
- female sex
- a long QT interval at baseline
- slow heart rate (bradycardia)
- heart disease
- QT-affecting or interacting drugs, including alcohol, cocaine and methadone
- CYP2D6 gene variants that change how ibogaine is broken down
Concerns specific to ketamine use. None of these has been studied directly.
- Electrolytes: vomiting from "K-cramps" may lower potassium.
- Liver: ketamine-related liver and bile-duct damage could change how ibogaine is cleared.
- Psychosis: ketamine can cause psychosis, which is relevant to psychiatric screening.
- Polysubstance use: cocaine and alcohol use are common alongside ketamine. Seizures during alcohol or benzodiazepine withdrawal were a risk factor in the fatality review.
- Drug combination: ketamine and ibogaine are both NMDA-active, and no safety data exist on combining them or on how long to wait between them.
Opioids. If you also use opioids, your tolerance falls after ibogaine treatment by an amount no one can predict, so a dose you used before can be a fatal overdose. Leave treatment with naloxone, and call emergency services if someone cannot be woken or is breathing poorly.
Seek emergency care for chest pain, fainting, palpitations or seizures.
Open questions and research gaps
Evidence on ibogaine for ketamine addiction is at the earliest possible stage. The main unanswered questions are:
- Efficacy: does ibogaine reduce ketamine use or craving more than standard care or placebo? No controlled data exist.
- Mechanism: why would an NMDA-blocking drug help with dependence on another NMDA blocker?
- Safety in this group: how do bladder, kidney and liver damage, and the electrolyte losses from K-cramps, change cardiac risk?
- Timing: how long after the last ketamine dose is it safe to give ibogaine?
- Durability: in the only published case, the patient needed a second treatment within a year.
- Bladder outcomes: does stopping ketamine by any route change how well the bladder recovers? No study has looked at this after ibogaine.
Conventional treatment also needs better evidence. The reviewers call for randomised trials of benzodiazepine withdrawal regimens and of medications for relapse prevention.
For now, the honest summary is this: ibogaine for ketamine use disorder is an untested hypothesis supported by one case report, and it carries well-documented cardiac risks.
Frequently Asked Questions
Can ibogaine treat ketamine addiction?
Nobody knows yet. The only published evidence is one 2026 case report of a man who stayed abstinent for about 17 months after ibogaine treatment in Mexico, and he needed a second treatment after a bereavement. No controlled trials or case series exist. A single case cannot show how often ibogaine helps, how often it harms, or whether the result came from ibogaine or from the support around it.
Is ibogaine safe after ketamine use?
This has not been studied. Ibogaine prolongs the QT interval, and people have died after taking it. Several features of heavy ketamine use could add risk in theory: vomiting can lower potassium, the liver and bile ducts may be damaged, and other drugs such as cocaine and alcohol are often used too. There are no data on safe waiting periods between ketamine and ibogaine.
What is the most effective treatment for ketamine addiction?
No single treatment is proven best, and no medication is approved for ketamine use disorder. Reviews suggest the most promising approach is integrated, multidisciplinary care that combines psychosocial therapy such as motivational interviewing or CBT, supervised withdrawal where needed, treatment for depression or anxiety, and urology care for bladder symptoms. Benzodiazepines, naltrexone and lamotrigine have been used, but the evidence for them is very low quality.
How long does ketamine withdrawal last?
The UK Advisory Council on the Misuse of Drugs says withdrawal after heavy use can last several days. Case reports describe craving, low mood and, in some people, psychotic symptoms or racing thoughts. Higher depression scores, stronger cravings and more frequent use have been linked to needing longer inpatient treatment. Because the evidence is limited, withdrawal is best planned with a doctor, especially if you also use alcohol or benzodiazepines.
Can the bladder recover after quitting ketamine?
Often it improves, but not always. Stopping ketamine is the most important step in treating ketamine-induced uropathy. The ACMD notes that long-term harms may not resolve, or may only partly resolve, after use stops, especially once scarring has occurred. Medicines, treatments delivered into the bladder and, in severe cases, surgery may be needed. Seeing a urologist early, alongside addiction care, gives the best chance of recovery.
Is ibogaine legal in the United States?
No. Ibogaine is listed in Schedule I of the US Controlled Substances Act (DEA code 7260), so it cannot legally be prescribed, and possessing or distributing it outside authorized research is illegal. Most people who seek it travel to countries such as Mexico. Treatment there is not regulated to US standards, and the authors of the ketamine case report described their patient's setting as unregulated.
How do I quit ketamine?
Start by talking to a doctor or a local addiction service, especially if you use ketamine daily, have bladder or abdominal pain, or also use alcohol, benzodiazepines or other drugs. They can plan a supervised withdrawal, offer talking therapies, treat depression or anxiety, and refer you to urology. Telling people you trust and avoiding situations where you used ketamine can also help. Relapse is common, and returning to treatment afterwards is normal.
Are there clinical trials of ibogaine for ketamine use disorder?
We found no registered or published controlled trials of ibogaine for ketamine use disorder. Most clinical research on ibogaine has involved opioid use disorder, and even there the studies are small, open-label and observational. The authors of the only ketamine case report call for controlled trials in regulated settings. Anyone offered ibogaine for ketamine addiction should know it is experimental.
References
- Advisory Council on the Misuse of Drugs, Ketamine – an updated review of use and harms (review of human and animal evidence), 2026
- Roberts E et al. The Pharmacological Management of Ketamine Use Disorder: A Systematic Review. Journal of addiction medicine, 2024
- Mosca A, Chiappini S, Schifano F, et al., Treatment and management approaches for ketamine misuse: A systematic review of medical interventions (human studies), Journal of Substance Use and Addiction Treatment, 2026
- Pérez Rosal SR, Faber SC, Backmund M, Sustained abstinence in severe ketamine use disorder following ibogaine treatment case report (single human patient), Frontiers in Psychiatry, 2026
- Ona G et al. Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: A mechanistic overview. Journal of psychopharmacology (Oxford, England), 2023
- Knuijver T et al. Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study. Addiction (Abingdon, England), 2022
- Koenig X et al. The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules (Basel, Switzerland), 2015
- Alper KR, Stajić M, Gill JR, Fatalities Temporally Associated with the Ingestion of Ibogaine (review of human fatalities), Journal of Forensic Sciences, 2012
- U.S. Drug Enforcement Administration, Diversion Control Division, Controlled Substances – Alphabetical Order, 2026